Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors

Xiao Hu; Angie Mae Rodday; Anastasia Gurinovich; Stacey Pan; Yana V Salei; Jeffrey H Lin; Margaret M Byrne; Yu Cao; Lori Pai; Susan K Parsons

doi:10.1080/1750743X.2025.2488728

Back

Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors

Journal article

Peer reviewed

Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors

Xiao Hu, Angie Mae Rodday, Anastasia Gurinovich, Stacey Pan, Yana V Salei, Jeffrey H Lin, Margaret M Byrne, Yu Cao, Lori Pai and Susan K Parsons

Immunotherapy, Vol.17(5), pp.321-329

03/24/2025

DOI: 10.1080/1750743X.2025.2488728

PMCID: PMC12045565

PMID: 40183219

View Online

Abstract

Immune-checkpoint inhibitors (ICIs) have revolutionized lung cancer (LC) treatment; however, immune-related adverse effects (irAEs) may occur. The risk factors of irAEs and the impact of irAEs on patient outcomes in LC remain uncertain. irAEs within 12 months of ICI initiation in LC patients who initiated ICIs 2018-2021 were identified. Cause-specific Cox regression was used to assess risk factors for irAEs with the competing risk of death; a subset analysis was done among non-small cell lung cancer (NSCLC) group. Multivariable Cox regressions were used to evaluate the impact of irAEs on progression-free survival (PFS) and overall survival (OS). Of 125 patients, 50 irAEs occurred in 39 patients. Small cell lung cancer (SCLC) histology was associated with a higher risk of irAEs (Hazard ratio (HR) = 2.73, 95% CI [1.17, 6.35], = 0.020) than NSCLC. In NSCLC subset, programmed death-ligand 1 (PDL1) positivity (HR = 2.68, 95% CI [1.10. 6.53], = 0.030) was identified as a risk factor. irAEs were not significantly associated with PFS (HR = 0.69, = 0.204) or OS (HR = 0.72, = 0.353). SCLC histology and PDL1 positivity were associated with irAEs, and the occurrence of irAEs showed no impact on survival in LC patients. Future studies are required to validate the findings.

Lung Cancer

risk factors

outcomes

immune-related adverse events

Immune-checkpoint inhibitors

Details

Title: Subtitle: Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors
Creators: Xiao Hu - MaineHealth
Angie Mae Rodday - Tufts Medical Center
Anastasia Gurinovich - Tufts Medical Center
Stacey Pan - Tufts Medical Center
Yana V Salei - Tufts Medical Center
Jeffrey H Lin - Tufts Medical Center
Margaret M Byrne - University of Iowa
Yu Cao - Tufts Medical Center
Lori Pai - Tufts Medical Center
Susan K Parsons - Tufts Medical Center
Resource Type: Journal article
Publication Details: Immunotherapy, Vol.17(5), pp.321-329
DOI: 10.1080/1750743X.2025.2488728
PMID: 40183219
PMCID: PMC12045565
NLM abbreviation: Immunotherapy
ISSN: 1750-7448
eISSN: 1750-7448
Publisher: TAYLOR & FRANCIS LTD
Grant note: National Center for Advancing Translational Sciences: UL1TR002544 Natalie V. Zucker Research Center for Women Scholars Award
This research was supported in part by an institutional research support grant: 2023 Natalie V. Zucker Research Center for Women Scholars Award (X.H.); REDCap software was supported by the National Center for Advancing Translational Sciences, National Institutes of Health [Grant Number UL1TR002544].
Language: English
Electronic publication date: 04/04/2025
Date published: 03/24/2025
Academic Unit: Internal Medicine
Record Identifier: 9984804798202771

Metrics

9 Record Views

See more details